Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 71-80 of 283 for Lung cancer

Edit search filters
  1. A Study of the Safety and Effectiveness of INC280 Alone and in Combination with Erlotinib, When Compared to Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutation and Amplified cMET

    Rochester, MN

  2. A Study To Evaluate MUC1 Vaccine To Prevent Lung Cancer In Current And Former Smokers At High Risk For Lung Cancer

    Rochester, MN

  3. A Study Of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) In Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel In Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

    Scottsdale/Phoenix, AZ

  4. Phase 3 Study Of Taletrectinib Vs Placebo As An Adjuvant Therapy In ROS1 Positive NSCLC (TRUST-IV)

    Rochester, MN

  5. A Study Of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody In Participants With Advanced Or Metastatic NSCLC

    Rochester, MN

  6. A Pilot, Randomized, Open-label Study Of Tumor Treating Fields (TTFields, 150 KHz) Concomitant With Pembrolizumab For First Line Treatment Of Advanced Or Metastatic Non-small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  7. Study Of VS-6766 + Adagrasib In KRAS G12C NSCLC Patients

    Jacksonville, FL, Rochester, MN

  8. Combination Therapies With Adagrasib In Patients With Advanced NSCLC With KRAS G12C Mutation

    Jacksonville, FL, Rochester, MN

  9. GMCI Plus Standard Of Care Immune Checkpoint Inhibitor For Stage III/IV NSCLC

    Rochester, MN

  10. A Study Of BH-30643 In Subjects With Locally Advanced Or Metastatic NSCLC Harboring EGFR And/or HER2 Mutations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer